MediWound at H.C. Wainwright: value trial looms as catalyst

MediWound (MDWD) showcased its enzymatic wound care platform at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting progress in burns and chronic wounds, as well as the upcoming VALUE trial for EscharEx as a major catalyst. The company's bromelain-based platform has been validated by 14 successful clinical trials, more than 150 publications, and regulatory approvals in the U.S., Europe, and Japan.

The VALUE trial, with 216 patient enrollment, is expected to provide interim results after approximately 65% of patients are recruited. MediWound's shares rose 4.92% to $13.755 in response to the positive outlook for its products, including EscharEx and NexoBrid. The company is also expanding its manufacturing capacity and anticipates European approval for a new facility around mid-2027.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.